Development of an effective neuropeptide-based therapeutic for treating anxiety and depression
Principal Investigator
Prof. Nitish R. Mahapatra
Objective
- To investigate the modulatory effect of the neuropeptide catestatin on the development of anxiety and depression symptoms., To decipher the mechanism of regulation of anxiety and depression symptoms., To determine the effects of intranasal catestatin treatment.
Description
- Stress-related psychiatric disorders including post-traumatic stress disorder, depression and anxiety, constitute up to 13% of the global disease burden, surpassing cancer and cardiovascular diseases., Treatment of these disorder is highly challenging, and it involves psychotherapy, neurological therapies and may include long-term medications such as anti-depressants., Neuropeptides are emerging as clinically relevant pharmacophores for treating stress-related disorders. Catestatin, a chromogranin A-derived neuropeptide, is as a potent physiological modulator of stress hormones.
Impact
- The sympatho-inhibitory peptide, catestatin is anticipated to emerge as an effective pharmacophore for treating psychiatric disorders including anxiety and depressive-like behaviours., It may also be useful for non-invasive prophylactic treatment or early intervention in response to traumatic stress., Successful completion of this pre-clinical study will lead to Phase-I clinical trial in near future.
Budget in Lakhs
90.00
Duration
3 Years